BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29728516)

  • 1. The Effect of Including Bone in Dixon-Based Attenuation Correction for
    Elschot M; Selnæs KM; Johansen H; Krüger-Stokke B; Bertilsson H; Bathen TF
    J Nucl Med; 2018 Dec; 59(12):1913-1917. PubMed ID: 29728516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of
    Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
    AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
    [No Abstract]   [Full Text] [Related]  

  • 4.
    Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
    Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid ZTE/Dixon MR-based attenuation correction for quantitative uptake estimation of pelvic lesions in PET/MRI.
    Leynes AP; Yang J; Shanbhag DD; Kaushik SS; Seo Y; Hope TA; Wiesinger F; Larson PE
    Med Phys; 2017 Mar; 44(3):902-913. PubMed ID: 28112410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian penalised likelihood reconstruction (Q.Clear) of
    Teoh EJ; McGowan DR; Schuster DM; Tsakok MT; Gleeson FV; Bradley KM
    Br J Radiol; 2018 May; 91(1085):20170727. PubMed ID: 29303359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A PET/MRI study towards finding the optimal [
    Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of quantification errors in pelvic and spinal lesions caused by ignoring higher photon attenuation of bone in [18F]NaF PET/MR.
    Schramm G; Maus J; Hofheinz F; Petr J; Lougovski A; Beuthien-Baumann B; Oehme L; Platzek I; van den Hoff J
    Med Phys; 2015 Nov; 42(11):6468-76. PubMed ID: 26520736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
    Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
    J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
    [No Abstract]   [Full Text] [Related]  

  • 11. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
    Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
    Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Almost 10 years of PET/MR attenuation correction: the effect on lesion quantification with PSMA: clinical evaluation on 200 prostate cancer patients.
    Bogdanovic B; Gafita A; Schachoff S; Eiber M; Cabello J; Weber WA; Nekolla SG
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):543-553. PubMed ID: 32725538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of Prostate Cancer Using Fluciclovine.
    Savir-Baruch B; Zanoni L; Schuster DM
    PET Clin; 2017 Apr; 12(2):145-157. PubMed ID: 28267449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body PET/MRI: the effect of bone attenuation during MR-based attenuation correction in oncology imaging.
    Aznar MC; Sersar R; Saabye J; Ladefoged CN; Andersen FL; Rasmussen JH; Löfgren J; Beyer T
    Eur J Radiol; 2014 Jul; 83(7):1177-1183. PubMed ID: 24780817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
    Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
    Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fasting Enhances the Contrast of Bone Metastatic Lesions in
    Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468238
    [No Abstract]   [Full Text] [Related]  

  • 17. One registration multi-atlas-based pseudo-CT generation for attenuation correction in PET/MRI.
    Arabi H; Zaidi H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2021-35. PubMed ID: 27260522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
    Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of
    Kim SJ; Lee SW
    Clin Radiol; 2019 Nov; 74(11):886-892. PubMed ID: 31358294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.